Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Stage/Subtype:  recurrent intraocular melanoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-8 of 8 for your search:
Start Over
Ipilimumab and Palliative Radiation Therapy in Treating Patients with Stage IV Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MEL0005, NCI-2011-03274, 21970, 5136, SU-08242011-8306, NCT01449279
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Epacadostat and Vaccine Therapy in Treating Patients with Stage III-IV Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-04, NCI-2013-01605, NCT01961115
Trametinib with or without GSK2141795 in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9445, NCI-2013-02091, 13-144, NCT01979523
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCT02363283
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 201103308, NCI-2011-00484, 07-0652, 201103308 / 07-0652, NCT00683670
Sotrastaurin Acetate and Alpelisib in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAN4901, NCI-2015-00753, CAEB071AUS01T, NCT02273219
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18377, NCI-2016-00358, NCT02652455
Start Over